In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...

which directs them to CD19 antigens on B-cell cancers. In the absence of the antibody, the CAR-T cells are dormant. The first readout from an ongoing phase 1 study reveals that, out of nine ...

CHICAGO--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy ... does not require plasmid DNA as critical ...

Catalent global cell therapy and plasmid DNA vice-president Delara ... GLPG5101 is an anti-cluster of differentiation 19 (CD19)/4-1BB CAR-T candidates, designed to be administered in a single ...